The stock of Amedisys Inc (AMED) has gone down by -1.69% for the week, with a -1.18% drop in the past month and a 1.15% rise in the past quarter. The volatility ratio for the week is 0.88%, and the volatility levels for the past 30 days are 0.73% for AMED. The simple moving average for the past 20 days is -1.42% for AMED’s stock, with a -3.13% simple moving average for the past 200 days.
Is It Worth Investing in Amedisys Inc (NASDAQ: AMED) Right Now?
Amedisys Inc (NASDAQ: AMED) has a price-to-earnings ratio of 36.27x that is above its average ratio. Additionally, the 36-month beta value for AMED is 0.77. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 9 rating it as “hold,” and 1 rating it as “sell.”
The public float for AMED is 32.04M and currently, short sellers hold a 7.95% ratio of that float. The average trading volume of AMED on February 21, 2025 was 440.27K shares.
AMED) stock’s latest price update
Amedisys Inc (NASDAQ: AMED)’s stock price has plunge by -1.64relation to previous closing price of 92.61. Nevertheless, the company has seen a -1.69% plunge in its stock price over the last five trading sessions. zacks.com reported 2025-02-12 that Amedisys (AMED) doesn’t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts’ Opinion of AMED
Many brokerage firms have already submitted their reports for AMED stocks, with Deutsche Bank repeating the rating for AMED by listing it as a “Hold.” The predicted price for AMED in the upcoming period, according to Deutsche Bank is $101 based on the research report published on July 29, 2024 of the previous year 2024.
Truist gave a rating of “Hold” to AMED, setting the target price at $97 in the report published on June 07th of the previous year.
AMED Trading at 1.04% from the 50-Day Moving Average
After a stumble in the market that brought AMED to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -7.94% of loss for the given period.
Volatility was left at 0.73%, however, over the last 30 days, the volatility rate increased by 0.88%, as shares sank -1.08% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +7.44% upper at present.
During the last 5 trading sessions, AMED fell by -1.69%, which changed the moving average for the period of 200-days by -1.45% in comparison to the 20-day moving average, which settled at $92.40. In addition, Amedisys Inc saw 0.33% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AMED starting from North Michael Paul, who proposed sale 11,221 shares at the price of $96.80 back on Nov 07 ’24. After this action, North Michael Paul now owns shares of Amedisys Inc, valued at $1,086,220 using the latest closing price.
Stock Fundamentals for AMED
Current profitability levels for the company are sitting at:
- 0.08 for the present operating margin
- 0.4 for the gross margin
The net margin for Amedisys Inc stands at 0.05. The total capital return value is set at 0.11. Equity return is now at value 7.58, with 3.98 for asset returns.
Based on Amedisys Inc (AMED), the company’s capital structure generated 0.29 points at debt to capital in total, while cash flow to debt ratio is standing at 0.45. The debt to equity ratio resting at 0.41. The interest coverage ratio of the stock is 5.64.
Currently, EBITDA for the company is 216.91 million with net debt to EBITDA at 1.12. When we switch over and look at the enterprise to sales, we see a ratio of 1.38. The receivables turnover for the company is 7.71for trailing twelve months and the total asset turnover is 1.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.19.
Conclusion
In conclusion, Amedisys Inc (AMED) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
